Showing 7851-7860 of 8879 results for "".
- Journey Medical Corporation Shares Positive Comparative Pharmacokinetic Data for DFD-29 for Rosaceahttps://practicaldermatology.com/news/journey-medical-corporation-shares-positive-comparative-pharmacokinetic-data-for-dfd-29-for-rosacea/2461473/Journey Medical Corporation shared positive PK comparability data of DFD-29 and key updates on the progress of its pivotal Phase 3 clinical study of DFD-29 for the treatment of papulopustular rosacea in collaboration with Dr. Reddy’s Laboratories Ltd. The PK study was designed as
- AMA Responds to Medicare Cutshttps://practicaldermatology.com/news/ama-responds-to-medicare-cuts/2461472/
- Soligenix Initiates Phase 2 Trial of SGX302 for Mild to Moderate Psoriasishttps://practicaldermatology.com/news/soligenix-initiates-phase-2-trial-of-sgx302-for-mild-to-moderate-psoriasis/2461471/Patient enrollment has been opened for Soligenix, Inc.'s Phase 2a study evaluating SGX302 (synthetic hypericin) for the treatment of mild to moderate psoriasis. "We are excited to expand synthetic hypericin's development into different cutaneous T-cell diseases such as psor
- Promising and Consistent Topline Results Seen in Phase 3 Trial of Roflumilast in ADhttps://practicaldermatology.com/news/promising-and-consistent-topline-results-seen-in-phase-3-trial-of-roflumilast-in-ad/2461466/Arcutis Biotherapeutics, Inc.’s roflumilast met the key primary and secondary endpoints in the INT
- Garnier Debuts Product Impact Ranking Across Hair Care Rangehttps://practicaldermatology.com/news/garnier-debuts-product-impact-ranking-across-hair-care-range/2461455/Garnier is launching a digital labeling system that ranks its hair care products versus other L'Oreal Group Products based on 14 environmental factors. Product Impact Labelling ranks each product from A to E, with "A" indicating the 10% of L'Oreal Group Products in the
- Celebrities Come Together for EB Research Partnershiphttps://practicaldermatology.com/news/celebrities-come-together-for-eb-research-partnership/2461453/EB Research Partnership
- James R. Headley Joins ELEVAI LABS as Strategic Advisorhttps://practicaldermatology.com/news/james-r-headley-joins-elevai-labs-as-strategic-advisor-a-strategic-advisor/2461450/Cosmetic industry veteran James R. Headley is joining
- Almirall Joins Project Aimed at Giving Clinical Trial Data Back to Study Participantshttps://practicaldermatology.com/news/almirall-joins-project-aimed-at-giving-clinical-trial-data-back-to-study-participants/2461446/Almirall is participating in FACILITATE (FrAmework for ClInicaL trIal participants’ daTA reutilization for a fully Transparent and Ethical ecosystem), a patient-driven Innovative Medicines Initiative (IMI) project that aims to create a framework for access and reutilization of clinical tria
- FDA Clears the Accure Laser System for the Treatment of Mild to Severe Inflammatory Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-the-accure-laser-system-for-the-treatment-of-mild-to-severe-inflammatory-acne-vulgaris/2461439/The FDA has cleared Accure Acne Inc's Accure Laser System to treat mild to severe inflammatory acne vulgaris. The Accure Laser System builds upon the unique selectivity of the 1726nm laser wavelength, adding proprietary technology to precisely control thermal gradient depth. This technology b
- Laser Could Prevent UV Radiation-Induced Damage to Skinhttps://practicaldermatology.com/news/laser-could-prevent-uv-radiation-induced-damage-to-skin/2461438/Incidence rates of squamous cell carcinomas (SCCs) are increasing, particularly in high-risk populations, including fair-skinned or immunosuppressed individuals. Few therapeutic options exist to prevent sunlight-induced skin cancer despite rising incidence rates. A recent study determined that ab